Trade-Ideas LLC identified

Intrexon

(

XON

) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Intrexon as such a stock due to the following factors:

  • XON has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $75.2 million.
  • XON has traded 94,083 shares today.
  • XON is up 5.2% today.
  • XON was down 7.5% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in XON with the Ticky from Trade-Ideas. See the FREE profile for XON NOW at Trade-Ideas

More details on XON:

Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. The stock currently has a dividend yield of 0.4%. Currently there are 4 analysts that rate Intrexon a buy, 1 analyst rates it a sell, and 1 rates it a hold.

The average volume for Intrexon has been 1.7 million shares per day over the past 30 days. Intrexon has a market cap of $4.3 billion and is part of the health care sector and drugs industry. Shares are up 15.4% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Intrexon as a

sell

. Among the areas we feel are negative, one of the most important has been weak operating cash flow.

Highlights from the ratings report include:

  • Net operating cash flow has decreased to -$16.52 million or 21.00% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Biotechnology industry and the overall market, INTREXON CORP's return on equity significantly trails that of both the industry average and the S&P 500.
  • INTREXON CORP has improved earnings per share by 30.2% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, INTREXON CORP reported poor results of -$0.84 versus -$0.03 in the prior year. This year, the market expects an improvement in earnings (-$0.40 versus -$0.84).
  • The gross profit margin for INTREXON CORP is rather high; currently it is at 67.79%. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of -90.58% is in-line with the industry average.
  • The company, on the basis of net income growth from the same quarter one year ago, has significantly outperformed against the S&P 500 and exceeded that of the Biotechnology industry average. The net income increased by 21.9% when compared to the same quarter one year prior, going from -$52.04 million to -$40.66 million.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.